Dynavax Technologies Corporation (DVAX)vsHaleon plc (HLN)
DVAX
Dynavax Technologies Corporation
$15.50
0.00%
HEALTHCARE · Cap: $1.82B
HLN
Haleon plc
$8.95
+1.79%
HEALTHCARE · Cap: $39.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 3237% more annual revenue ($11.03B vs $330.51M). HLN leads profitability with a 15.1% profit margin vs -0.1%. HLN earns a higher WallStSmart Score of 63/100 (C+).
DVAX
Hold45
out of 100
Grade: D+
HLN
Buy63
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 92.0% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
0.2% revenue growth
0.7% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.2%
Expensive relative to growth rate
0.6% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DVAX
DVAX has a balanced fundamental profile.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, P/E Ratio, Price/Book. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : DVAX
The primary concerns for DVAX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
DVAX profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
DVAX carries more volatility with a beta of 0.93 — expect wider price swings.
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 45/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dynavax Technologies Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global consumer health company formed from a spin-off of GlaxoSmithKline, focusing on delivering innovative health solutions across a diverse portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. By concentrating on key segments such as oral care, pain relief, and dietary supplements, Haleon effectively addresses the dynamic needs of consumers while capitalizing on strong brand equity. The company's dedication to sustainability and relentless innovation, combined with strategic investments in product development, positions it advantageously for sustained long-term growth, thereby enhancing health outcomes and maximizing shareholder value.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?